These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
69 related articles for article (PubMed ID: 10967712)
21. The effect of CYP2D6 polymorphisms on dextromethorphan metabolism in Mexican Americans. Casner PR J Clin Pharmacol; 2005 Nov; 45(11):1230-5. PubMed ID: 16239355 [TBL] [Abstract][Full Text] [Related]
22. Study of GM immunoglobulin allotypic system in Berbers and Arabs from Morocco. Coudray C; Guitard E; Kandil M; Harich N; Melhaoui M; Baali A; Sevin A; Moral P; Dugoujon JM Am J Hum Biol; 2006 Jan; 18(1):23-34. PubMed ID: 16378347 [TBL] [Abstract][Full Text] [Related]
23. Simultaneous genotyping of CYP2D6*3, *4, *5 and *6 polymorphisms in a Spanish population through multiplex long polymerase chain reaction and minisequencing multiplex single base extension analysis. Crescenti A; Mas S; Gassó P; Baiget M; Bernardo M; Lafuente A Clin Exp Pharmacol Physiol; 2007 Oct; 34(10):992-7. PubMed ID: 17714084 [TBL] [Abstract][Full Text] [Related]
24. Nicotine metabolism and CYP2D6 phenotype in smokers. Caporaso NE; Lerman C; Audrain J; Boyd NR; Main D; Issaq HJ; Utermahlan B; Falk RT; Shields P Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):261-3. PubMed ID: 11303596 [TBL] [Abstract][Full Text] [Related]
25. [Mitochondrial DNA polymorphism reveals a genetic differentiation between ethnic groups in the population of Jerba]. Yacoubi Loueslati B; Ennafaa H; Ben Amor M; Heyer E; Langaney A; Ben Ayed F; Ben Ammar Elgaaied A Arch Inst Pasteur Tunis; 1998; 75(1-2):9-18. PubMed ID: 14722942 [TBL] [Abstract][Full Text] [Related]
26. Identification of CYP2D6 null variants among long-stay, chronic psychiatric inpatients: is it strictly necessary? Fernández-Santander A; Santiago C; Díez-Durán S; González M; de Castro E; Guijarro J; Bandrés F; Lucia A; Gómez-Gallego F Hum Psychopharmacol; 2008 Aug; 23(6):533-6. PubMed ID: 18425996 [TBL] [Abstract][Full Text] [Related]
27. The effect of a long term epidural infusion of ropivacaine on CYP2D6 activity. Wink J; Veering BT; Kruit M; Burm AG; Huledal GA; Ekström GY; Stienstra R; van Kleef JW Anesth Analg; 2008 Jan; 106(1):143-6, table of contents. PubMed ID: 18165569 [TBL] [Abstract][Full Text] [Related]
29. [Study of debrisoquine hydroxylation polymorphism (CYP2D6) in the Cuban population compared to Spaniards]. González I; Pérez B; Alvarez M; Dorado P; Llerena A Med Clin (Barc); 2007 May; 128(20):772-4. PubMed ID: 17568504 [TBL] [Abstract][Full Text] [Related]
30. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Ingelman-Sundberg M Pharmacogenomics J; 2005; 5(1):6-13. PubMed ID: 15492763 [TBL] [Abstract][Full Text] [Related]
31. Genetic polymorphisms of CYP2D6 in Chinese mainland. Ji L; Pan S; Wu J; Marti-Jaun J; Hersberger M Chin Med J (Engl); 2002 Dec; 115(12):1780-4. PubMed ID: 12622923 [TBL] [Abstract][Full Text] [Related]
32. A study of Gm allotypes and immunoglobulin heavy gamma IGHG genes in Berbers, Arabs and sub-Saharan Africans from Jerba Island, Tunisia. Loveslati BY; Sanchez-Mazas A; Ennafaa H; Marrakchi R; Dugoujon JM; Lefranc JM; Elgaaied AB Eur J Immunogenet; 2001 Oct; 28(5):531-8. PubMed ID: 11881820 [TBL] [Abstract][Full Text] [Related]
33. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. Stamer UM; Musshoff F; Kobilay M; Madea B; Hoeft A; Stuber F Clin Pharmacol Ther; 2007 Jul; 82(1):41-7. PubMed ID: 17361124 [TBL] [Abstract][Full Text] [Related]
34. Rapid high-performance liquid chromatographic method for determination of debrisoquine and 4-hydroxy-debrisoquine in urine for CYP2D6 phenotyping. Svensson JO; Bertilsson L Pharmacogenetics; 1999 Aug; 9(4):529-31. PubMed ID: 10780273 [No Abstract] [Full Text] [Related]
35. Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine. Sachse C; Brockmöller J; Hildebrand M; Müller K; Roots I Pharmacogenetics; 1998 Apr; 8(2):181-5. PubMed ID: 10022755 [No Abstract] [Full Text] [Related]
36. Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians. Dalén P; Dahl ML; Roh HK; Tybring G; Eichelbaum M; Wilkinson GR; Bertilsson L Br J Clin Pharmacol; 2003 Jun; 55(6):630-4. PubMed ID: 12814461 [TBL] [Abstract][Full Text] [Related]
37. New allelic arrangement CYP2D6*36 x 2 found in a Japanese poor metabolizer of debrisoquine. Chida M; Ariyoshi N; Yokoi T; Nemoto N; Inaba M; Kinoshita M; Kamataki T Pharmacogenetics; 2002 Nov; 12(8):659-62. PubMed ID: 12439227 [No Abstract] [Full Text] [Related]
38. Adverse drug reactions and debrisoquine/sparteine (P450IID6) polymorphism in patients with fibromyalgia. Skeith KJ; Hussain MS; Coutts RT; Ramos-Remus C; Avina-Zubieta JA; Russell AS Clin Rheumatol; 1997 May; 16(3):291-5. PubMed ID: 9184268 [TBL] [Abstract][Full Text] [Related]
39. Debrisoquine and N-acetylation polymorphism in Syria. Roustom R; Siegmund W; Zschiesche M; Franke G Int J Clin Pharmacol Ther Toxicol; 1992 Nov; 30(11):543-4. PubMed ID: 1490826 [No Abstract] [Full Text] [Related]
40. Alu polymorphisms in Jerba Island population (Tunisia): comparative study in Arab and Berber groups. Ennafaa H; Amor MB; Yacoubi-Loueslati B; Khodjet el-khil H; Gonzalez-Perez E; Moral P; Maca-Meyer N; Elgaaied A Ann Hum Biol; 2006; 33(5-6):634-40. PubMed ID: 17381061 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]